Uromigos-Prostate Cancer

The UromigosThe Uromigos | February 26, 2024
Vania Wisdom, Senior Executive Editor at The Lancet, discusses cancer treatment and research in developing countries.
Listen Now
The UromigosThe Uromigos | February 7, 2024
Dr. Dana Rathkopf describes the phase 1 data for the androgen receptor ligand-directed degrader in prostate cancer.
The UromigosThe Uromigos | January 30, 2024
Dr. Agarwal discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for mCRPC.
The UromigosThe Uromigos | January 30, 2024
Dr. Kim Chi discusses the BRCAAway and CONTACT-02 trials presented at ASCO GU 2024.
The UromigosThe Uromigos | January 30, 2024
Dr. Himisha Beltran, describes the activity of novel agent HPN328 in neuroendocrine prostate cancer.
The UromigosThe Uromigos | January 30, 2024
Neeraj Agarwal describes the results of the phase III CONTACT-02 trial on cabozantinib plus atezolizumab in prostate cancer. ...
The UromigosThe Uromigos | January 30, 2024
Karim Fizazi, MD, PhD, joins the show to discuss the phase III TALAPRO-2 trial published in Nature.
The UromigosThe Uromigos | January 11, 2024
Thomas Zilli joins the podcast to talk about the controversies surrounding radiotherapy for prostate cancer.
The UromigosThe Uromigos | January 11, 2024
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue at APCCC 2024.
The UromigosThe Uromigos | January 11, 2024
Silke Gillessen gives an overview of APCCC 2024 taking place in Lugano, Switzerland, in April.
The UromigosThe Uromigos | December 20, 2023
The Uromigos close out the year with Tanya Dorff, MD, as she discusses her favorite prostate cancer studies of 2023.
The UromigosThe Uromigos | January 30, 2024
Dr. Rahul Aggarwal discusses his recent paper on a phase 1/2 study on Lu-177 with pembrolizumab for mCRPC.
The UromigosThe Uromigos | October 31, 2023
Dr. Kevin Kelly discusses the AMG509 phase 1 study of xaluritamig, a bispecific T cell engager, for prostate cancer.
The UromigosThe Uromigos | October 30, 2023
Louise Emmett discusses the phase 2 ENZA-p trial presented at ESMO 2023 on enzalutamide and 177Lu-PSMA-617 for mCRPC.
The UromigosThe Uromigos | October 11, 2023
Dr. Nick James discusses the optimal patients to undergo radiotherapy for localized prostate cancer.
The UromigosThe Uromigos | October 5, 2023
Dr. Michalski discusses brachytherapy techniques in prostate cancer, plus his work on a recent JCO article on the topic.
The UromigosThe Uromigos | September 28, 2023
Jim Catto, PhD, FRCS, joins The Uromigos to discuss the 17-year follow-up data from the PROTECT prostate cancer study.
The UromigosThe Uromigos | September 14, 2023
Dr. Susan F. Slovin discusses her recent paper that examined abiraterone with and without cabazitaxel for mCRPC.
The UromigosThe Uromigos | August 8, 2023
Chana Weinstock, MD joins the podcast to give career advice and answer our questions about the FDA.
The UromigosThe Uromigos | August 1, 2023
We're joined by Walter M. Stadler, MD, to discuss how academic papers are accepted and the steps to take when submitting one.
Advertisement
Advertisement